Myeloma Center

You are here

Bibliography

Found 56 results
Author Title Type [ Year(Desc)]
2013
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.  2013.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.. Leukemia. 27(8):1707-14.
Rosenbaum C, Jasielec J, Laubach J, Prada CPaba, Richardson P, Jakubowiak AJ.  2013.  Evolving strategies in the initial treatment of multiple myeloma.. Semin Oncol. 40(5):592-601.
Dimopoulos MA, Terpos E, Niesvizky R.  2013.  How lenalidomide is changing the treatment of patients with multiple myeloma.. Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.
Niesvizky R.  2013.  Immunomodulatory agents changing the landscape of multiple myeloma treatment.. Crit Rev Oncol Hematol. 88 Suppl 1:S1-4.
Siegel D, Martin T, Nooka A, R Harvey D, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K et al..  2013.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.. Haematologica. 98(11):1753-61.
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T.  2013.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R.  2013.  Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.. Blood. 122(18):3122-8.
Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.  2013.  Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. Br J Haematol. 163(4):478-86.
Richardson PG, Mark TM, Lacy MQ.  2013.  Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.. Crit Rev Oncol Hematol. 88 Suppl 1:S36-44.
Kwon D, Niesvizky R.  2013.  Treatment of multiple myeloma with carfilzomib in patients with renal injury.. Clin Adv Hematol Oncol. 11(9):605-6.